Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 1;12(6):e8399.
doi: 10.7759/cureus.8399.

Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines

Affiliations
Review

Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines

Christopher Manners et al. Cureus. .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging human coronavirus responsible for coronavirus disease 2019 (COVID-19), a predominantly respiratory disease that has become a global pandemic. Millions of people worldwide are suffering from COVID-19, and hundreds of thousands of those infected have died. Nevertheless, many more people who have been infected with SARS-CoV-2 are asymptomatic or suffer a mild disease characterized by dry cough and mild fever. This new pandemic poses a threat to public health on a global scale, and an intervention to prevent continued spread of SARS-CoV-2 virus is of the utmost importance. To assess preventive and therapeutic strategies, it is imperative to understand the pathogenesis and immune response against SARS-CoV-2. In this review, we concentrate on the protective adaptive immune response elicited by this novel coronavirus as well as requirements for a successful vaccine inducing optimal protection.

Keywords: covid-19; neutralizing antibodies; sars-cov-2; t-cell immunity; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Privileges and immunity certification during the COVID-19 pandemic [Epub ahead of print] Hall MA, Studdert DM. JAMA. 2020 - PubMed
    1. A comprehensive review of severe acute respiratory syndrome coronavirus 2. Baek W, Sohn S, Mahgoub A, Hague R. Cureus. 2020;12:7943. - PMC - PubMed
    1. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. Perreau M, Pantaleo G, Kremer EJ. J Exp Med. 2008;205:2717–2725. - PMC - PubMed
    1. Antibody-dependent enhancement of severe dengue disease in humans. Katzelnick LC, Gresh L, Halloran ME, et al. Science. 2017;358:929–932. - PMC - PubMed
    1. Brief history and characterization of enhanced respiratory syncytial virus disease. Acosta PL, Caballero MT, Polack FP. Clin Vaccine Immunol. 2016;23:189–195. - PMC - PubMed

LinkOut - more resources